BrightOwl Loader Loading

Summary

Energetic, results oriented pharma research leader with 14 years of experience in successfully leading oncology projects throughout the research and development value chain, heading multidisciplinary oncology research departments and global project teams and establishing and overseeing external collaborations.

Experiences

Current Experience

  • Senior Vice President Research & Pre-Clinical Development
    Since March 2016

Past Experience

  • Department Head DTA Oncology & Preclinical Science Leader MDM2 Franchise
    April 2013 --- March 2016
    • Heading and managing a multidisciplinary oncology research department consisting of 14 research labs including molecular biology, cell biology, biochemistry and in-vivo pharmacology labs supporting projects and assets from early target validation to marketed drugs with a strong focus on cancer immunotherapy and cell signaling/apoptosis projects • Responsible for 65 people, including 14 PhD level co-workers (lab heads) • Preclinical head of the MDM2 franchise program leading the global research project teams in different phases of discovery and development. Fully responsible and accountable for the preclinical research strategy including evaluation of new drug combinations and cancer indications and establishment of collaborations with KOLs, biotech companies and CROs • Preclinical representative for all MDM2 project related interactions with health authorities and responsible for IND and IB generation • Member of the DTA Oncology Penzberg leadership team, defining the future research direction and strategy in alignment with the global DTA Oncology team

  • Research Director
    September 2012 --- April 2013
    • Assigned as preclinical representative within the MDM2 franchise program (two molecules in Phase 1, one molecule in Phase 0, one molecule in late preclinical, one asset in early preclinical phase) supervising the global project teams and all ongoing research activities including management of support functions (CMC, DMPK, formulation, non-clinical safety), external collaboration and budget planning • Led and managed the collaboration with a biotech company located in the US to develop MDM2 targeted stapled peptides • Responsible for the successful and seamless transition of all preclinical research activities within the MDM2 franchise program to the research sites in Europe (Basel/Switzerland and Penzberg/Germany) due to the closure of the Nutley site. • Transition manager responsible to ensure a smooth phase-out of the research activities and shutting down the research labs in time together with the local management team • Member of due diligence teams evaluating in-licensing opportunities of small molecule and protein drug candidates

  • Head Preclinical Research, Academic Alliances
    April 2010 --- September 2012
    • Member of the due diligence team evaluating the research and development capabilities in Singapore, responsible for the preclinical research strategy and implementation during the TM Hub establishment and set-up, established Roche as the partner of choice on the ground • Single point of contact and “bridge” between the oncology top management at Roche, the TM Hub and the external investigators in Singapore • Responsible for the delivery of strategies and studies to the Oncology Discovery Head and to the Global Head of Academic Alliances • Responsible and accountable for all preclinical research activities across all therapeutic areas within the Singapore TM Hub Singapore including a multi-million preclinical research budget/year • Established a flexible and highly virtual approach to enable drug discovery and development through a network of partnerships including academic institutes, hospitals and CROs • Facilitated, managed and guided the interaction between the Roche internal project teams and Singapore institutes • Supervision of one coworker (Manager Preclinical Research, PhD level position)

  • Program Manager External Innovation Discovery Oncology
    July 2007 --- April 2010
    • Actively reached out to academic institutes and biotech companies to find new targets/technologies/drug candidates for the DTA Oncology • Negotiated the scientific content, implemented and managed preclinical research collaborations • Evaluated on a regular basis preclinical research opportunities derived from the Roche Pharma Partnering organization • Scientific input and advice in multiple due diligences

  • Department Head Discovery Oncology
    January 2008 --- January 2010
    • Led a highly interdisciplinary staff of 25 co-workers, including PhDs and lab techs, divided into five research labs (molecular biology, biochemistry, cell biology, two in-vivo pharmacology labs) • Defined department strategy together with the research leadership team at Roche Penzberg. proposed and implemented the change initiative away from a technology based department structure to a research area focused department structure • Managed operational and capital budget, forecasting and reporting • Led various small molecule and antibody projects in oncology, from target proposal/assessment to Lead Optimization phase • Head of “Team New Targets”, responsible for assessing new target proposals from Roche research scientists as well as opportunities from outside to ensure a constant flow of new targets to enter into the global oncology portfolio

  • Lab Head Discovery Oncology
    October 2002 --- March 2008
    • Responsible for 4 co-workers (lab tech level) • Main focus on protein purification and characterization, mode-of-action analysis (in-vitro and ex-vivo), assay development and prevalence analysis • Member of the “Team New Targets” evaluating new target opportunities • Proposed and led various small molecule and antibody projects in oncology and hematology including external collaborations with biotech and academia

  • Post Doc Discovery Oncology
    May 2001 --- September 2002
    Main tasks: Protein and antibody purification and characterization/analysis, functional assay set up, potency assays, supervising one lab tech and diploma student(s)

Knowledge

LinkedIn Assessment :
Drug DiscoveryoncologyPharmaceuticalsTranslational MedicineTranslational ResearchTarget IdentificationscienceClinical trialsPharmaceutical IndustryBiotechnologyToxicologyBiomarker DiscoverypharmacologyAssay developmentDrug DevelopmentIn VivoImmunologyAntibodiesmolecular biologyBioinformaticsLife SciencesBiomarkersLifesciencesClinical DevelopmentIn VitroBiochemistryBiopharmaceuticals

Education

  • Dr. in Biochemistry from Leopold-Franzens Universität Innsbruck in 2001

Area / Region

Munich, Germany

Others

Driving License
  • No